Jun 29, 2024, 15:03
IO inductive therapy let 25% unresectable stage 3 NSCLC become resectable
Thomas Wu, Research physician at Genentech, shared a post by X:
“Our paper just out on Cancer Cell: IO inductive therapy let 25% unresectable stage 3 NSCLC become resectable and more patients without recurrence than that received CCRT.
Thanks all investigators from 15 sites in China. It is impossible without their hard works!”
Patrick Forde, Co-Director of Division of Upper Aerodigestive Malignancies at John Hopkins, added:
“Outstanding work from Dr. Thomas Wu and colleagues, leading the next generation of studies in earlier stage lung cancer! I had the pleasure of being a reviewer for this manuscript, highly recommend!”
Source: Thomas Wu/X and Patrick Forde/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 22, 2025, 11:28
Feb 22, 2025, 11:22
Feb 22, 2025, 11:15
Feb 22, 2025, 11:02
Feb 22, 2025, 10:47
Feb 22, 2025, 05:18